XML 41 R16.htm IDEA: XBRL DOCUMENT v3.23.2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
 6 Months Ended
Jun. 30, 2023
Payables and Accruals [Abstract]  
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consists of the following (in thousands): 
 June 30, 2023December 31, 2022
Product revenue allowances$23,303 $26,268 
Product return reserves, current portion4,626 7,789 
Clinical trial costs754 5,755 
Compensation and related benefits6,582 11,481 
Operating lease liabilities, current portion4,757 4,744 
Royalties3,198 3,804 
Professional fees2,800 1,886 
Accrued manufacturing costs5,578 4,310 
Restructuring costs334 2,751 
Other4,476 6,989 
Total accrued expenses and other current liabilities$56,408 $75,777 
Accrued manufacturing costs includes the costs associated with the Company's commercial product Auryxia and vadadustat for which the Company is seeking approval from the FDA to market in the U.S. and for which the Company recently signed a license agreement with Medice to market in Europe and other territories (see Note 5 for further details).